- February-March 2025: The stock traded in the $0.60-$0.70 range, showing typical biotech volatility
- April-June 2025: Gradual decline to the $0.24-$0.40 range—classic “waiting period” before major catalysts
- July 2025: Explosive movement with daily volatility averaging 11.15%, including a 14.79% intraday swing
- August 2025: The big breakout—surged 163.59% in one month following positive earnings and clinical updates
How to Buy Ovid Therapeutics Inc. (OVID) Shares - Investment in Ovid Therapeutics Inc. (OVID) Stock
Updated on 25 Aug 2025
Thinking about investing in the cutting-edge world of neurological medicine? Ovid Therapeutics Inc. (OVID) represents one of the most exciting—and volatile—opportunities in the biotech sector. This company is pioneering treatments for brain disorders that affect millions worldwide, making it a potential game-changer for both patients and investors. Let's explore what makes this stock so compelling and how you can strategically add it to your portfolio.
Article navigation
- 📈 Ovid Therapeutics Stock: Current Price and Critical Dates
- 🔍 6-Month Price Journey: Rollercoaster Ride
- 🔮 Price Forecast: 2025-2030 Outlook
- ⚠️ Key Risks vs. Positive Signals
- 🛡️ What Should a Beginner Trader Do Today?
- ✅ How to Buy Ovid Therapeutics Inc. (OVID) Shares – Step by Step
- 💡 Why Pocket Option Fits New Biotech Investors
- 🌍 Ovid Therapeutics in 2025: Neuroscience Innovator
📈 Ovid Therapeutics Stock: Current Price and Critical Dates
As of August 25, 2025, Ovid Therapeutics Inc. (OVID) trades at $1.03 per share. But mark your calendar: November 2025 could be explosive for this stock. That’s when the company is expected to release its next earnings report, and based on recent history, these events move OVID dramatically.
How Earnings Reports Impact OVID Stock
The most recent earnings on August 13, 2025, sent shockwaves through the market. The company reported revenue of $6.27 million—a staggering 3,611% increase from the same period last year! Despite posting a net loss of $4.68 million due to increased R&D spending, the stock surged an incredible 52.61% in the following trading session (AInvest Report).
This pattern isn’t new. Biotech stocks like OVID live and die by clinical trial results and earnings surprises. The upcoming November report could be equally dramatic, especially with key data readouts expected for their OV329 treatment.
🔍 6-Month Price Journey: Rollercoaster Ride
OVID’s price action over the past six months has been nothing short of breathtaking:
Why such dramatic moves? OVID represents the pure essence of biotech investing: high risk, high reward. The stock hit its 52-week low of $0.24 and high of $1.47 within this period, showing the extreme range potential (StockInvest Data).
🔮 Price Forecast: 2025-2030 Outlook
- 2025 Year-End: $3.10-$7.14 range (200-578% potential upside) → STRONG BUY
Analysts are overwhelmingly bullish, with an average price target of $3.10 and technical models predicting up to $7.14 (StockScan Forecast). The key catalyst? OV329 Phase 1 data expected in Q3 2025. - 2026 Forecast: $0.495-$3.50 range
Divergence here reflects the binary nature of biotech—either the clinical trials succeed (higher range) or face challenges (lower range). - 2028 Projection: $0.225-$1.00
Long-term models show conservative estimates, but successful drug approvals could dramatically change this outlook. - 2030 Outlook: Highly speculative
By 2030, if OVID’s pipeline delivers even one approved drug, the stock could multiply significantly. However, this remains the riskiest part of the forecast.
⚠️ Key Risks vs. Positive Signals
Risks to Consider:
- Cash burn: Less than one year of runway remaining despite $38.3M cash position
- Clinical trial failures: Phase 1 data for OV329 could disappoint investors
- Extreme volatility: 11.15% average daily swings can test any investor’s nerves
- Dilution risk: High probability of additional stock offerings to fund operations
Green Lights for 2025:
- Revenue explosion: 3,611% YoY growth shows business model potential
- Pipeline progress: OV329 Phase 1 data expected Q3 2025—major catalyst
- Strategic deals: $7M royalty agreement with Immedica extends cash runway
- Industry tailwinds: CNS disorder treatments represent a $150B+ market opportunity
🛡️ What Should a Beginner Trader Do Today?
- Start small: Allocate no more than 2-5% of your portfolio to high-risk biotech like OVID
- Dollar-cost average: Buy in small increments rather than one large purchase
- Set stop-losses: Protect yourself from the extreme downside volatility
- Monitor catalysts: Mark November 2025 earnings and Q3 clinical data dates
Humorous take: “Trading OVID is like dating a neuroscientist—brilliant potential, emotionally unpredictable, and requires strong stomach medication!”
✅ How to Buy Ovid Therapeutics Inc. (OVID) Shares – Step by Step
| Step | Action | Why It Matters |
|---|---|---|
| 1 | Choose a trading platform | Ensure it offers NASDAQ access and OVID availability |
| 2 | Complete account verification | Most platforms require ID and proof of address |
| 3 | Deposit funds | Start with an amount you’re comfortable potentially losing |
| 4 | Search for “OVID” | Use the ticker symbol, not just the company name |
| 5 | Select order type | Use limit orders to control your entry price in volatile stocks |
| 6 | Review and confirm | Double-check quantity and price before executing |
| 7 | Monitor your position | Set price alerts for major movement levels |
💡 Why Pocket Option Fits New Biotech Investors
For those looking to dip their toes into volatile biotech stocks like OVID, Pocket Option offers several advantages:
- Minimum deposit of just $5—perfect for testing strategies with small amounts
- Lightning-fast verification—start trading within minutes with basic documentation
- Diverse withdrawal options—access your profits through multiple convenient methods
The platform’s user-friendly interface makes navigating biotech volatility much less intimidating for newcomers.
🌍 Ovid Therapeutics in 2025: Neuroscience Innovator
Ovid Therapeutics stands at the forefront of neurological medicine, developing breakthrough treatments for conditions that have frustrated doctors for decades. The company’s focus on GABA aminotransferase inhibitors and KCC2 activators represents some of the most promising science in the CNS space.
With a market cap around $60 million, OVID remains a small-cap gem with massive potential. The company’s recent revenue explosion—from $0.17M to $6.27M in one year—shows their business model is gaining traction (Official Investor Report).
Interesting Fact: In 2025, Ovid’s research team discovered that their lead compound OV329 not only reduces seizures but also appears to improve cognitive function in preclinical models—a potential dual benefit that could revolutionize epilepsy treatment!
FAQ
Is OVID stock too risky for beginners?
Yes, extremely. Biotech stocks require strong risk tolerance and should represent only a small portion of any portfolio.
What's the biggest near-term catalyst for OVID?
Phase 1 clinical trial results for OV329 expected in Q3 2025—this could make or break the stock short-term.
How much cash does Ovid have remaining?
Approximately $38.3 million as of June 2025, expected to fund operations into early second half of 2026.
What makes OVID different from other biotech companies?
Their focus on novel mechanisms for CNS disorders and recent explosive revenue growth set them apart.
Should I buy before or after earnings reports?
For volatile stocks like OVID, many investors wait until after earnings to avoid surprise results, though this means potentially missing big moves.
Signals
Sign up for more like this
Customize your newsfeed with content you're actually interested in — get up-to-date personalized newsletter in your inbox.
Your comment
Comments are pre-moderated to ensure they comply with our blog guidelines.